Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)

被引:8
|
作者
Tariq, Arsalan [1 ,2 ]
McGeorge, Stephen [1 ,2 ]
Pearce, Adam [1 ,2 ,4 ]
Rhee, Handoo [2 ,5 ]
Wood, Simon [2 ,5 ]
Kyle, Samuel [6 ,7 ]
Marsh, Philip [6 ]
Raveenthiran, Sheliyan [1 ,3 ]
Wong, David [8 ]
McBean, Rhiannon [8 ]
Westera, Jurjen [1 ,2 ]
Dunglison, Nigel [1 ,2 ]
Esler, Rachel [1 ,4 ]
Navaratnam, Anojan [1 ,2 ]
Yaxley, John [1 ,2 ,4 ]
Thomas, Paul [2 ,7 ]
Pattison, David A. [2 ,7 ]
Roberts, Matthew J. [1 ,2 ,3 ,9 ]
机构
[1] Royal Brisbane & Womens Hosp, Dept Urol, Brisbane, Qld, Australia
[2] Univ Queensland, Fac Med, Brisbane, Qld, Australia
[3] Redcliffe Hosp, Dept Urol, Redcliffe, Qld, Australia
[4] Wesley Hosp, Wesley Urol Clin, Brisbane, Qld, Australia
[5] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia
[6] Princess Alexandra Hosp, Dept Diagnost Radiol, Brisbane, Qld, Australia
[7] Royal Brisbane & Womens Hosp, Dept Nucl Med, Brisbane, Qld, Australia
[8] Wesley Hosp, I MED Radiol, Brisbane, Qld, Australia
[9] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia
关键词
Renal cancer; Tumor thrombus; Staging; Positron emission tomography; Prostate specific membrane antigen; Magnetic resonance imaging; INFERIOR VENA-CAVA; SURGICAL-MANAGEMENT; PORTAL-VEIN; EXPRESSION; MRI; PET;
D O I
10.1016/j.urolonc.2022.03.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Venous tumor thrombus (TT) occurs as part of the natural history of renal cell carcinoma (RCC) local progression in a small minority of cases. MRI is currently the most accurate imaging modality for determining TT extent. PSMA PET/CT may improve RCC staging and IVC TT characterization. The objective of this study was to investigate the role of PSMA PET/CT in defining superior extent of TT in RCC and TT IVC tributary vessel spread, with comparative accuracy vs. MRI, to assess suitability for resection and inform preoperative surgical planning. Methods: Patients who underwent PSMA PET/CT for assessment of renal malignancywith TT from 2015 to 2020 at 3 tertiary hospitals in Brisbane, Australia, were retrospectively identified. TT extent was classified using Mayo Clinic levels and compared according to imagingmodality. Results: Fourteen patients were included, all of which were clear cell RCC. Ten patients also underwent MRI, 6 of which were concordant in extent according to MRI and PSMA PET. Discordant extent occurred in 4 patients, of which 2 patients had non-PSMA avid thrombus (Mayo level 0 and level 3 on MRI). Further discordance was seen in a patient with adrenal vein and lumbar vein TT only seen on MRI and PSMA PET/CT, respectively. Finally, discordant extent was seen in another patient with Mayo level 4 TT without lumbar vein involvement on MRI vs. level 3 on PSMA PET/CT with lumbar vein involvement. Conclusions: PSMA PET/CT can provide additional information about TT extent in RCC which may not be seen on MRI. Additional information from PSMA PET/CT in this setting may assist surgical planning, in addition to detection of metastatic disease. (c) 2022 Elsevier Inc. All rights reserved.
引用
下载
收藏
页码:276.e1 / 276.e9
页数:9
相关论文
共 50 条
  • [1] Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC).
    Pathmanathan, Shivanshan
    Tariq, Arsalan
    Gan, Chun Loo
    Pearce, Adam
    Rhee, Handoo
    Kyle, Samuel
    Raveenthiran, Sheliyan
    Wong, David
    McBean, Rhiannon
    Marsh, Philip
    Goodman, Steven
    Dhiantravan, Nattakorn
    Esler, Rachel
    Dunglison, Nigel
    Navaratnam, Anojan
    Yaxley, John
    Thomas, Paul
    Pattison, David A.
    Goh, Jeffrey C.
    Roberts, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Stellenwert der PSMA-PET/CT („prostate-specific membrane antigen positron emission tomography/computed tomography“) im Rahmen des StagingsRole of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging
    Claudia Kesch
    Tobias Franiel
    Christoph Berliner
    Wolfgang P. Fendler
    Ken Herrmann
    Boris Hadaschik
    Die Urologie, 2025, 64 (3) : 220 - 228
  • [3] A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC)
    Ahn, Thomas
    Roberts, Matthew J.
    Abduljabar, Aous
    Joshi, Andre
    Perera, Marlon
    Rhee, Handoo
    Wood, Simon
    Vela, Ian
    MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (05) : 799 - 807
  • [4] A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC)
    Thomas Ahn
    Matthew J. Roberts
    Aous Abduljabar
    Andre Joshi
    Marlon Perera
    Handoo Rhee
    Simon Wood
    Ian Vela
    Molecular Imaging and Biology, 2019, 21 : 799 - 807
  • [5] Characterisation of Tumour Thrombus in Renal Cell Carcinoma with Prostate Specific Membrane Antigen Positron Emission Tomography
    Tariq, Arsalan
    McGeorge, Stephen
    Pearce, Adam
    Rhee, Handoo
    Kyle, Samuel
    Marsh, Philip
    Raveenthiran, Sheliyan
    Wong, David
    McBean, Rhiannon
    Westera, Jurjen
    Dunglison, Nigel
    Esler, Rachel
    Navaratnam, Anojan
    Yaxley, John
    Thomas, Paul
    Pattison, David
    Roberts, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 47 - 48
  • [6] Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
    Udovicich, Cristian
    Callahan, Jason
    Bressel, Mathias
    Ong, Wee Loon
    Perera, Marlon
    Tran, Ben
    Azad, Arun
    Haran, Shankar
    Moon, Daniel
    Chander, Sarat
    Shaw, Mark
    Eapen, Renu
    Goad, Jeremy
    Lawrentschuk, Nathan
    Murphy, Declan G.
    Hofman, Michael
    Siva, Shankar
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 44 : 60 - 68
  • [7] Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
    Song, Rachel
    Jeet, Varinder
    Sharma, Rajan
    Hoyle, Martin
    Parkinson, Bonny
    PHARMACOECONOMICS, 2022, 40 (08) : 807 - 821
  • [8] Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
    Rachel Song
    Varinder Jeet
    Rajan Sharma
    Martin Hoyle
    Bonny Parkinson
    PharmacoEconomics, 2022, 40 : 807 - 821
  • [9] Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer
    Shayegan, Bobby
    Zukotynski, Katherine
    Benard, Francois
    Menard, Cynthia
    Kuk, Joda
    Sistani, Golmehr
    Bauman, Glenn
    Veit-Haibach, Patrick
    Metser, Ur
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (06): : 162 - 172
  • [10] The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
    Veerman, Hans
    Donswijk, Maarten
    Bekers, Elise
    Bodar, Yves J. L.
    Meijer, Dennie
    van Moorselaar, R. Jeroen A.
    Oprea-Lager, Daniela E.
    van Der Noort, Vincent
    van Leeuwen, Pim J.
    Vis, Andre N.
    van der Poel, Henk G.
    BJU INTERNATIONAL, 2022, 130 (06) : 750 - 753